@entity0 with chest wall progression: treatment with XXXX .

@entity1 @entity17654 @entity0 @entity66 @entity5 @entity158 @entity34
BACKGROUND: Chest wall progression of @entity0 affects up to 5% of @entity0 @entity1 and is a major source of their @entity158 . Treatment options are limited or may not be offered to these @entity1 . Low-dose @entity17654 -induced @entity34 ( @entity34 ) offers an excellent clinical response with minimal morbidity. We report our continued experience with @entity34 in this setting. METHODS: Fourteen @entity1 with more than 500 truncal metastases were treated with @entity34 . All received off-label @entity17654 (.8 mg/kg) i.v. and light treatment at 630 nm from a diode laser with a microlens at a fluence of 1800 mW and a total light dose of 150 to 200 J/cm2 at 48 hours. One @entity1 required re-treatment because of @entity66 . RESULTS: Follow-up was at least 6 months, and several extended to >24 months. All @entity1 demonstrated @entity5 necrosis, with 9 of 14 complete responses, including with lesions >2 cm in thickness. Disease progression occurred outside of the treatment field. Several @entity1 had initial regression of untreated lesions. Wound care, especially with disease in the deep tissues, was an issue. CONCLUSIONS: Low-dose @entity17654 -induced @entity34 offers @entity1 with chest wall progression a treatment option with an excellent clinical response. To date, the response is prolonged and offers good local control. Surgical oncologists have an active role in this treatment option.
